Hamartoma of the breast: a clinicopathological review

G M K Tse, B K B Law, T K F Ma, A B W Chan, L-M Pang, W C W Chu, H S Cheung

ORIGINAL ARTICLE


See end of article for authors’ affiliations

Correspondence to:
Dr G M K Tse, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Ngan Shing Street, Shatin, NT, Hong Kong SAR, China; garytse@cuhk.edu.hk

Accepted for publication 7 August 2002

Aims: To review 25 cases of breast hamartoma and discuss the pathological criteria, and the usefulness of imaging modalities, fine needle aspiration cytology (FNAC), and needle core biopsy in the diagnosis.

Methods: The hamartomas were assessed for interlobular fibrotic stroma, stromal adipose tissue content, pseudo-angiomatous stromal hyperplasia, and epithelial changes (hyperplasia, adenosis or apocrine metaplasia, and cyst formation). All imaging, previous FNACs, and biopsies were also reviewed.

Results: Imaging (mammography, ultrasound, and magnetic resonance imaging) was performed in 18 cases, and mostly showed encapsulated masses with a heterogeneous appearance. Microscopically, all hamartomas demonstrated good demarcation with fibrous tissue condensation. Adipose tissue was noted in all cases (5–90%; mean, 31%), and interlobular fibrosis in 21 cases. Benign epithelial hyperplasia occurred in 10 cases, and pseudo-angiomatous stromal hyperplasia or cystic ducts in eight cases each. Apocrine metaplasia, calcification, stromal giant cells, and adenosis occurred in four cases or less. Two cases showed coexisting ductal carcinoma in situ limited to within the hamartoma. Needle core biopsies (four cases) and FNAC (14 cases) were largely insufficient, inconclusive, or nonspecific.

Conclusions: Hamartomas do not possess specific diagnostic histological features. The role of FNAC and needle core biopsy in making the diagnosis is limited, and requires clinical and radiological correlation to avoid underdiagnosis.

The term hamartoma was first coined by Arrigoni et al in 1971, as a well circumscribed breast lesion with varying amounts of benign epithelial elements, fibrous tissue, and fat. Many authors consider this entity to be underdiagnosed. Pathologically, a distinctive appearance is lacking. Several little used morphological patterns have been described. With the increasing use of diagnostic procedures on breast lumps, including mammography, ultrasound, fine needle aspiration cytology (FNAC), and needle core biopsy, it is expected that more hamartomas will be picked up. In contradistinction to many other benign or malignant breast lesions, the diagnosis of hamartoma can easily be missed if the clinical impression of a distinct lump or breast asymmetry and the imaging features are not taken into consideration when the biopsy is examined. For breast lumps, FNAC has become a commonly performed and reliable diagnostic test. The value of FNAC in diagnosing mammary hamartoma has not been evaluated. We report a series of 25 cases of hamartoma, and discuss the usefulness of these various increasingly popular diagnostic modalities in the diagnosis of mammary hamartoma.

“Many authors consider hamartoma to be underdiagnosed”

MATERIALS AND METHODS

The histopathology files of the authors (GMKT, TKFM) were searched for mammary hamartomas from 1984 to 2001. Clinical follow-up data were obtained. All previous imagings were reviewed by the radiologists. The specimens had been formalin fixed, routinely processed, and 4 µm sections had been haematoxylin and eosin stained and examined for several morphological features considered to be characteristic of hamartoma. These included fibrotic stroma extending between individual breast lobules, adipose tissue in the stroma, pseudo-angiomatous stromal hyperplasia, with a network of inter-anastomising vascular-like channels lined by flattened cells, and epithelial changes including epithelial hyperplasia, apocrine metaplasia, adenosis, and cyst formation. The adipose tissue content of the stroma was determined by estimating the percentage area of adipose tissue after reviewing all the slides for each case. For those cases with previous biopsies or FNAC, the respective slides were also reviewed and reviewed. The original diagnoses and adequacy of the specimen were assessed.

RESULTS

In total, 25 cases of hamartoma were retrieved from 1984 to 2001. These 25 hamartomas were obtained from 24 patients, with one patient having two hamartomas in the same breast with an interval of 10 months. Two cases had coexisting ductal carcinoma in situ (DCIS; one micropapillary type, another solid and cribriform type with early focal invasion). These had been reported previously. All the patients were women, and the age range was 24 to 76 years (mean, 38).

Clinically, most (23) patients presented with painless, soft to firm palpable breast lumps, and the clinical impression was fibroadenoma. One patient presented with gross breast asymmetry. Twelve hamartomas were on the left and 13 were on the right. Imaging was performed in 18 patients. In four patients, ultrasound, mammography, and magnetic resonance imaging (MRI) were done, with all cases showing features characteristic of “lipofibroadenoma” or hamartoma. For the remaining 14 patients, all had ultrasound and seven also had mammography. The mammograms were diagnosed descriptively as mixed fibrous and adipose tissue without suspicion of malignancy. In mammography, the hamartomas appeared as ovoid to rounded, well circumscribed masses of mixed heterogeneous

Abbreviations: DCIS, ductal carcinoma in situ; FNAC, fine needle aspiration cytology; MRI, magnetic resonance imaging
Internal fat intensity was demonstrated in all lesions. A dark smooth thin rim, ovoid in shape with internal heterogeneity, displacing the adjacent normal breast tissue. In mammography, density with a mottled centre. Thin smooth capsules with peripheral radiolucent zones were seen (fig 1A). In sonography, they were also well encapsulated with echogenic rims and internal inhomogeneity, displacing the adjacent normal breast tissue.

Twenty four lesions were resected (lumpectomy); the single remaining case was diagnosed by biopsy and the patient was followed only because she refused surgery. All patients were followed for two months to four years before the cases were closed. All patients were well, with only one patient developing a recurrence after an interval of 10 months. For this patient, the histological features of the original and recurrent hamartomas were similar, and the initial resection was incomplete, with the presence of lesion at the margin. This patient was well without further complications after another one year follow up period. The lesion sizes ranged from 1.2 to 14 cm (mean, 3.8). Gross examination revealed nodular masses that were rounded and possessed smooth outlines (fig 2A). They were soft to firm, and some appeared to be shelled out at the time of surgery. The cut surface showed variable fatty areas within a fibrotic stroma. Clefs and fronds were not prominent.

Microscopy showed that the nodules were well demarcated from the adjacent breast tissue (fig 2B). Condensation of fibrous tissue around the mass was seen. In 21 cases, there was dense hyalinised fibrotic tissue between the individual lobules. In all cases, adipose tissue was noted within the stroma in variable amounts, ranging from 5% to 90% (mean, 31%) in area (fig 2C). In eight cases, the stroma showed areas of pseudo-angiomatous changes (fig 2D).

discussion

Mammary hamartoma has a reported incidence of 0.1% to 0.7%. The true incidence is probably higher, as pointed out by Daya et al, Fehner, and substantiated by our own experience that with the increasing use of breast imaging more hamartomas are likely to be identified.

Hamartoma has the typical mammographic appearance of lucent lesions containing fat, varying radio dense fibrous and fibrofatty stroma. Early attempts to subclassify hamartomas according to the histological parameters resulted in a confusing state of affairs. A three category classification of the “fibrous”, “fatty”, and “fibro fatty” hamartoma has been put forward by McGuire and Cohn, and Jones et al suggested a four category classification of “encapsulated fibrocystic changes”, “fibroadenoma with fibrous stroma”, “fibroadenoma-like”, and “circumscribed adenolipoma”.

Neither of these descriptive classification systems has been widely adopted. The current criteria used by practising pathologists have not been described in a detailed manner. Fehner has described the difference in lobular distribution and the presence of fat in hamartomas as the differentiating features against the more common fibroadenomas. In the literature, several good reviews have been published encompassing moderate numbers of cases. In most of these

**Figure 1**  (A) Mammography showing an ovoid, well circumscribed mass of mixed density with fat, a mottled centre, and a thin smooth capsule. (B) Sonography showing well encapsulated mass with an echogenic rim and internal inhomogeneity, displacing the adjacent normal breast tissue.
series, efforts were devoted to the identification of definitive histological criteria. Different authors had used different criteria, but overlap exists.

The presence of lobules within a fibrotic stroma, which surrounds and extends to between individual lobules and obliterates the usual interlobular specialised loose stroma, is most characteristic. Most authors have alluded to this interlobular fibrosis. The same is seen in our series of 25 cases, in which most showed such a feature. However, this feature is not unique to hamartomas. In sclerosing lobular hyperplasia (fibroadenomatoid mastopathy), which is a well defined, rounded mass with enlarged lobules showing increased numbers of intralobular glands, the presence of interlobular stromal sclerosis mimics hamartoma. Its frequent association with fibroadenoma, and the absence of fat in the stroma, may help to distinguish sclerosing lobular hyperplasia from hamartoma.

Adipose tissue within the stroma is also commonly reported in hamartomas. In most series, adipose tissue is present in more than 90% of the cases, although the volume of adipose tissue generally accounts for 10–20% of the lesion volume. Charpin et al reported cases consisting of up to 70% fat. We report similar findings, with fat being present in all cases, and ranging from 5% to 90%, with a mean volume of 31% of the hamartoma.

The presence of pseudo-angiomatous stroma within the hamartoma has been reviewed and described in detail by Fisher et al. Subsequent experience by other authors found this to be a constant observation, even though the incidence varies from a high 71% to a low 16–20%. In our series, pseudo-angiomatous stroma was found in 32% of the hamartomas.

“The correct identification of hamartoma is important because there are the problems of recurrence and coincidental epithelial malignancy”

Epithelial changes were also seen in our series. Simple epithelial hyperplasia without atypia occurred in 40%, whereas cystic changes occurred in 32%, apocrine metaplasia was present in 16%, overlapping with cystic changes, and adenosis occurred in 4%. Cystic changes with or without concomitant apocrine metaplasia was also reported as a common feature of mammary hamartoma, even though in another series cystic changes were present in 20% of the cases reported. In our series, 32% showed significant cyst formation.

Other rare features that have been described in the literature, but occurring in a smaller proportion of cases include microcalcification, myoid (smooth muscle) differentiation, stromal oedema, and stromal giant cells. To add to the list is one case with focal ossification within the stroma of the hamartoma seen in our series.
For all the features that have been evaluated, none is unique to hamartoma. The presence of fibrosis or hyaline fibrosis within the stroma can be seen in a variety of breast lesions, including fibroadenoma, in which it constitutes the major differential diagnosis, as well as sclerosing lobular hyperplasia. Within the spectrum of fibrocystic changes, sclerosis, stromal fibrosis, apocrine metaplasia, and cystic changes of the ducts are common; pseudo-angiomatous changes in the stroma have also been reported in many types of breast lesions.17

The correct identification of hamartoma is important because there are the problems of recurrence and coincidental epithelial malignancy. In the series of Daya et al.,2 two of 25 cases occurred after local excision, after an interval of seven and 18 months, and in our series, one lesion recurred after 10 months. This is different from the experience of other authors, who reported no recurrences.2 5–8 10 More experience is clearly needed. Furthermore, there are occasional case reports5–8 10 of coincidental in situ or invasive ductal or lobular carcinoma occurring in hamartomas. Although such cases are rare, it is imperative for the pathologist to be diligent in sampling hamartomas for suspicious areas.

The use of FNAC in diagnosing breast lesions has now been well established and proved to be accurate. The role of FNAC in diagnosing hamartoma remains limited. In the literature, only one report has commented on its lack of usefulness in this respect.14 In another cytology report of a single case of FNAC of a breast hamartoma,12 a diagnostic label could not be assigned to the FNAC specimen, although the hamartoma was confirmed by the histology of the excision specimen. Similar findings occurred in our series, in which none of the hamartomas was diagnosed correctly at FNAC. The two main contributing factors are the scanty materials obtained during the aspiration and the lack of specific cytological or architectural features in hamartoma. For the rare cases in which the FNACs were of moderate to high cellularity, differentiation from fibroadenoma was not possible. Even core biopsy is of limited value, especially when the imaging findings or the clinical impressions were not provided.

Diagnosing hamartoma of the breast is difficult, especially in biopsy or FNAC. The pathologist who sees fibrous tissue within the lobules, or fibrous tissue and fat in the stroma with or without pseudo-angiomatous changes, should be alerted to the possibility of a hamartoma. Correlation with the imaging findings and clinical impression may avoid the embarrassing situation of diagnosing “no significant pathology” in a palpable, radiologically distinct lesion. The radiologist who performs FNAC or needle core biopsy should remember that FNAC can rarely yield sufficient sample for diagnosis, and that both FNAC and needle biopsy are unlikely to provide enough information for the pathologist. Good communication of imaging findings is essential. The surgeon should also realise that although hamartomas are benign, coincidental malignancy may occur, and the issue of potential recurrences has not been resolved.

Authors’ affiliations
G M K Tse, A B W Chan, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong SAR, China
B K B Law, Department of Surgery, Prince of Wales Hospital
L-M Pang, W C W Chu, Department of Diagnostic Radiology and Organ Imaging, Prince of Wales Hospital
T K F Ma, Department of Pathology, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China
H S Cheung, Department of Radiology, International Islamic University, Kuantan, Malaysia

REFERENCES
Hamartoma of the breast: a clinicopathological review

G M K Tse, B K B Law, T K F Ma, A B W Chan, L-M Pang, W C W Chu and H S Cheung

doi: 10.1136/jcp.55.12.951

Updated information and services can be found at:
http://jcp.bmj.com/content/55/12/951

These include:

References

This article cites 18 articles, 2 of which you can access for free at:
http://jcp.bmj.com/content/55/12/951#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Clinical diagnostic tests (805)
Breast cancer (506)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/